Codex DNA Announces Plan to Change Corporate Name to Telesis Bio
October 12 2022 - 9:00AM
Codex DNA, Inc. (Nasdaq: DNAY), a leader in automated multi-omic
and synthetic biology solutions, today announced a plan to change
its Company name to Telesis Bio.
“Our innovative and pioneering spirit, and the versatility and
power of our technologies, have enabled us to expand our portfolio
to include an array of tools for both synthetic biology and
genomics applications. To reflect the expansion, we are announcing
a name change to Telesis Bio,” said Todd Nelson PhD, CEO of Codex
DNA.
“Codex DNA was founded on innovation and a mission to inspire
and empower researchers to accelerate discovery of scientific
breakthroughs. We have introduced many firsts in synthetic biology,
enabled by our versatile and powerful BioXp® automation platform
and technologies including Gibson Assembly®, SOLA enzymatic DNA
synthesis (EDS), and proprietary error correction methods.
Furthering our mission, we have leveraged our capabilities to now
provide automated, benchtop solutions for multi-omics applications.
Telesis Bio reflects that expansion and growth,” stated Dr.
Nelson.
The new name reflects the focus, strategic vision, and growth of
the Company. There will be no change to corporate structure nor
financial reporting.
About Codex DNACodex DNA is empowering
scientists with the ability to create novel, synthetic
biology-enabled solutions for many of humanity’s greatest
challenges. As inventors of the industry-standard Gibson Assembly®
method and the first commercial automated benchtop DNA and mRNA
synthesis system, Codex DNA is enabling rapid, accurate, and
reproducible writing of DNA and mRNA for numerous downstream
markets. The award-winning BioXp® system consolidates, automates,
and optimizes the entire synthesis, cloning, and amplification
workflow. As a result, it delivers virtually error-free synthesis
of DNA and RNA at scale within days and hours instead of weeks or
months. Scientists around the world are using the technology in
their own laboratories to accelerate the design-build-test paradigm
for novel, high-value products for precision medicine, biologics
drug discovery, vaccine and therapeutic development, genome
editing, and cell and gene therapy. Codex DNA is a public Company
based in San Diego, CA. For more information,
visit codexdna.com.
Codex DNA, the Codex DNA logo, Gibson Assembly, BioXp, and
RapidAMP are trademarks of Codex DNA Inc.
Forward-Looking StatementsThis press release contains
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, as amended. Such
forward-looking statements are based on Codex DNA’s beliefs and
assumptions and on information currently available to it on the
date of this press release. Forward-looking statements may involve
known and unknown risks, uncertainties and other factors that may
cause Codex DNA’s actual results, performance, or achievements to
be materially different from those expressed or implied by the
forward-looking statements. These and other risks are described
more fully in Codex DNA’s filings with the Securities and Exchange
Commission (“SEC”) and other documents that Codex DNA subsequently
files with the SEC from time to time. Except to the extent required
by law, Codex DNA undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made.
Media Contact:
Charlie Schmidt
Sr. Director of Marketing
charlie@codexdna.com
Codex DNA (NASDAQ:DNAY)
Historical Stock Chart
From Sep 2024 to Oct 2024
Codex DNA (NASDAQ:DNAY)
Historical Stock Chart
From Oct 2023 to Oct 2024